This is a preview of subscription content, log in via an institution to check access.
Reference
Gulacsi L, et al. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. Advances in Therapy : 10 Apr 2017. Available from: URL: http://doi.org/10.1007/s12325-017-0522-y
Rights and permissions
About this article
Cite this article
Introduction of rituximab biosimilar cost saving in EU. PharmacoEcon Outcomes News 777, 22 (2017). https://doi.org/10.1007/s40274-017-3961-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3961-4